Zions Bancorporation National Association UT Reduces Holdings in Amgen Inc. $AMGN

Zions Bancorporation National Association UT trimmed its stake in Amgen Inc. (NASDAQ:AMGN) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,605 shares of the medical research company’s stock after selling 2,561 shares during the period. Zions Bancorporation National Association UT’s holdings in Amgen were worth $7,399,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC lifted its position in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the period. Schnieders Capital Management LLC. lifted its position in Amgen by 29.3% during the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after acquiring an additional 5,853 shares during the period. Main Street Financial Solutions LLC lifted its position in Amgen by 11.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after acquiring an additional 416 shares during the period. Finally, Ieq Capital LLC lifted its position in Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after acquiring an additional 2,611 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Down 2.0%

Shares of Amgen stock opened at $337.73 on Thursday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $182.28 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.46 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29. The company has a 50-day simple moving average of $340.89 and a two-hundred day simple moving average of $345.53.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Analysts Set New Price Targets

AMGN has been the subject of a number of recent research reports. Royal Bank Of Canada lifted their price target on shares of Amgen from $360.00 to $370.00 and gave the company an “outperform” rating in a research report on Tuesday, April 7th. Argus lowered their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Barclays initiated coverage on shares of Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price for the company. Morgan Stanley lifted their target price on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 target price on shares of Amgen in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $354.12.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.